Coherus, J&J agree to evaluate combination prostate cancer treatment
Source: SeekingAlpha
2026-02-04 10:17:09 ET
More on Coherus Oncology
- Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
- Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript
- Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential
- Seeking Alpha’s Quant Rating on Coherus BioSciences
Read the full article on Seeking Alpha
For further details see:
Coherus, J&J agree to evaluate combination prostate cancer treatment
Coherus BioSciences Inc.
NASDAQ: CHRS
CHRS Trading
1.27% G/L:
$1.6507 Last:
579,941 Volume:
$1.69 Open:
CHRS Latest News
March 09, 2026 04:15:00 pm
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
March 02, 2026 09:30:00 am
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
February 17, 2026 04:11:28 pm
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
CHRS Stock Data
$262,894,453
111,104,635
0.81%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
